Kynam Capital Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001907884

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2023 · 28 positions · Total reported value $550.53M · Top-10 concentration 83.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 48.8% · 4 new · 7 cut · 9 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +14.0% · vs SPY -0.8% · Prev Value $1.55B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2023 13F filing, Kynam Capital Management, LP disclosed 28 equity positions with a combined reported value of $550.53M. The filing implies a focused portfolio: its ten largest positions account for 83.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were NTRA ($132.91M), CLDX ($88.06M), PCVX ($66.40M). By sector, the heaviest allocations are Health Care 91.3%, Other 8.7%.

Versus the prior quarter, Kynam Capital Management, LP opened 4 new positions, trimmed 7 and fully exited 9, a turnover rate of 48.8% of positions.

The largest new positions opened in Q3 2023 were NTRA ($132.91M), CLDX ($88.06M), PCVX ($66.40M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • NTRA NATERA INC · $132.91M
  • CLDX CELLDEX THERAPEUTICS INC NEW · $88.06M
  • PCVX VAXCYTE INC · $66.40M
  • VERA VERA THERAPEUTICS INC · $40.53M
  • PTGX PROTAGONIST THERAPEUTICS INC · $30.34M
  • TSVT 2SEVENTY BIO INC · $23.34M
  • WVE WAVE LIFE SCIENCES INC · $22.61M
  • BCRX BIOCRYST PHARMACEUTICALS INC · $22.18M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Kynam Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Kynam Capital Management, LP files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $1.81B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • SEC registration: 801-126187 (status: Approved), registered 2022-07-22
  • Regulatory AUM (Form ADV): $2.41B as of 2026-04-10
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 32 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 72.7% of reported value
  • Largest position: CLDX (CELLDEX THERAPEUTICS INC NEW) at 10.9%
  • Average position size: $56.54M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 12 added, 7 reduced, 9 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 91.3%
Other 8.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 3.00M $132.91M 24.14%
24.14%
New
2 3.20M $88.06M 16.00%
16.00%
New
3 1.30M $66.40M 12.06%
12.06%
New
4 2.96M $40.53M 7.36%
7.36%
New
5 1.82M $30.34M 5.51%
5.51%
New
6 5.95M $23.34M 4.24%
4.24%
New
7 3.93M $22.61M 4.11%
4.11%
New
8 3.13M $22.18M 4.03%
4.03%
New
9 2.21M $21.55M 3.91%
3.91%
New
10 2.00M $12.68M 2.30%
2.30%
New
11 1.20M $12.20M 2.22%
2.22%
New
12 12.02M $11.06M 2.01%
2.01%
New
13 699.68K $10.73M 1.95%
1.95%
New
14 3.28M $10.37M 1.88%
1.88%
New
15 8.50M $8.24M 1.50%
1.50%
New
16 500.00K $7.38M 1.34%
1.34%
New
17 400.00K $5.81M 1.05%
1.05%
New
18 1.55M $5.39M 0.98%
0.98%
New
19 1.07M $5.11M 0.93%
0.93%
New
20 730.47K $4.73M 0.86%
0.86%
New
21 100.00K $3.84M 0.70%
0.70%
New
22 235.18K $2.90M 0.53%
0.53%
New
23 473.98K $1.25M 0.23%
0.23%
New
24 535.00K $434.00K 0.08%
0.08%
New
25 250.00K $208.20K 0.04%
0.04%
New
26 15.10K $134.99K 0.03%
0.03%
New
27 24.04K $94.95K 0.02%
0.02%
New
28 90.06K $43.44K 0.01%
0.01%
New

FAQ

What did Kynam Capital Management, LP buy in 2023-Q3?

In its 2023-Q3 13F filing, Kynam Capital Management, LP reported 28 equity positions worth $550.53M in aggregate; its largest disclosed positions were NTRA ($132.91M), CLDX ($88.06M), PCVX ($66.40M).

How large is Kynam Capital Management, LP's portfolio?

Kynam Capital Management, LP reported $550.53M of long equity holdings across 28 positions as of 2023-Q3. Top-10 holdings account for 83.7% of reported value.

What is Kynam Capital Management, LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/kynam-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →